Search results
Results From The WOW.Com Content Network
Amlodipine/valsartan, sold under the brand name Exforge among others, is a blood pressure lowering combination drug. It contains amlodipine, as the besilate, a dihydropyridine -type calcium channel blocker, and valsartan, an angiotensin II receptor antagonist. [6] This combination is usually well tolerated and effective for the reduction of ...
Valsartan, sold under the brand name Diovan among others, is a medication used to treat high blood pressure, heart failure, and diabetic kidney disease. [8] It belongs to a class of medications referred to as angiotensin II receptor blockers (ARBs).
Irbesartan, sold under the brand name Aprovel among others, is a medication used to treat high blood pressure, heart failure, and diabetic kidney disease. [5] It is a reasonable initial treatment for high blood pressure. [5] It is taken by mouth. [5] Versions are available as the combination irbesartan/hydrochlorothiazide. [5] [6] [7] [8]
For premium support please call: 800-290-4726 more ways to reach us
Valsartan, first marketed by Novartis, is a nonheterocyclic ARB, where the imidazole of losartan has been replaced by an acylated amino acid. [ 1 ] Irbesartan was developed by Sanofi Research and is longer acting than valsartan and losartan and it has an imidazolinone ring where a carbonyl group functions as a hydrogen bond acceptor instead of ...
Antihypertensive therapy seeks to prevent the complications of high blood pressure, such as stroke, heart failure, kidney failure and myocardial infarction. Evidence suggests that reduction of the blood pressure by 5 mmHg can decrease the risk of stroke by 34% and of ischaemic heart disease by 21%, and can reduce the likelihood of dementia ...
Later in 2021 and 2022, several cases of contamination with azido impurities were detected in losartan, irbesartan, and valsartan, prompting regulatory responses ranging from investigation to market withdrawals and precautionary recalls in Australia, [79] Brazil, [80] and Europe (including Switzerland). [81] [82]
Valsartan recall [ edit ] In 2018, valsartan manufactured by the company was voluntarily recalled due to the detection of trace amounts of N -nitrosodiethylamine (NDEA) which is a probable human carcinogen.